Butibufen, formerly known as FF-106, is a cyclooxygenase inhibitor used to treat inflammatory and rheumatic disorders. utibufen was within the potency range of ibuprofen as an antipyretic and analgesic agent and greater than that of acetylsalicylic acid. The compound possesses the advantage of a low order to toxicity. Its ulcerogenicity was much lower than that of phenylbutazone. Therefore, butibufen appears to offer potential safety and efficacy in the treatment of rheumatic diseases. Butibufen was now withdraw from the market. References: Hoult JR, Jackson BR, Benicka E, Patel BK, Hutt AJ. Chromatographic resolution, chiroptical characterization and preliminary pharmacological evaluation of the enantiomers of butibufen: a comparison with ibuprofen. J Pharm Pharmacol. 1999 Oct;51(10):1201-5. PubMed PMID: 10579692.

纯度：≥98%

CAS：55837-18-8